Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Maxygen and Roche terminate development of hepatitis drug
December 2007
SHARING OPTIONS:

REDWOOD CITY, Calif.-Maxygen Inc. and Roche have agreed to terminate development of MAXY-alpha, also known as R7025, and to end the agreement under which Maxygen licensed MAXY-alpha to Roche. MAXY-alpha was designed to be a next-generation alpha interferon for treating hepatitis C and hepatitis B infections. The news follows Maxygen's announcement of Sept. 21, 2007, that Roche had voluntarily placed a hold on the program. The MAXY-alpha program was fully funded by Roche, with no milestone payments expected in 2007 or 2008. As such, Maxygen expects no near-term impact on its financials as a result of the termination. Upon termination of the agreement, all rights to Maxygen's interferon variant product candidates revert back to Maxygen.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.